Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 10/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448317 | 1.00 | CDK2 (0.37) | CDK2MAPTALDH1A1HPGDHTT | |
| SCHEMBL6621616 | 0.95 | CDK2 (0.35) | CDK2MAPTALDH1A1HPGDHTT | |
| SCHEMBL6621622 | 0.95 | CDK2 (0.35) | CDK2MAPTALDH1A1HPGDHTT | |
| SCHEMBL3557097 | 0.87 | MAPT (0.38) | MAPTALDH1A1HPGDHTTTDP1 | |
| SCHEMBL3557099 | 0.87 | MAPT (0.38) | MAPTALDH1A1HPGDHTTTDP1 | |
| SCHEMBL4023024 | 0.86 | MAPT (0.32) | CDK2MAPTALDH1A1HPGDHTT | |
| SCHEMBL4023022 | 0.86 | MAPT (0.32) | CDK2MAPTALDH1A1HPGDHTT | |
| SCHEMBL5335810 | 0.82 | MAPT (0.36) | MAPTALDH1A1HPGDHTTTDP1 | |
| SCHEMBL5335807 | 0.82 | MAPT (0.36) | MAPTALDH1A1HPGDHTTTDP1 | |
| SCHEMBL278962 | 0.79 | MAPT (0.40) | MAPTALDH1A1HPGDHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-7442697-B2 | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | MOTOROLA MOBILITY LLC | 2006-04-06 | — | — | US | disclosed |
| EP-1490354-A1 | 4-IMIDAZOLYL SUBSTITUTED PYRIMIDINE DERIVATIVES WITH CDK INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003076434-A1 | 4- IMIDAZOLYL SUBSTUITED PYRIMIDINE DERIVATIVES WITH CDK INHIBITIORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | CDK2 4/4885MAPT 4106/4885ALDH1A1 1127/4885 |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | CDK2 13/4885MAPT 3364/4885ALDH1A1 423/4885 |
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | CCNI, CDK3, CDK4 | CDK2 6/4885MAPT 4365/4885ALDH1A1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.